**Name of Journal: *World Journal of Clinical Pediatrics***

**Manuscript No: 21915**

**Manuscript Type: MINIREVIEWS**

**Short and long term prognosis in perinatal asphyxia: An update**

Ahearne C *et al.* Prognosis in perinatal asphyxia

**Caroline Ahearne, Geraldine Boylan, Deirdre Murray**

**Caroline Ahearne, Geraldine Boylan, Deirdre Murray,** Department of Paediatrics and Child Health, University College Cork, Cork T12 YN60, Ireland

**Caroline Ahearne, Geraldine Boylan, Deirdre Murray,** Irish Centre for Fetal and Neonatal Translational Research (INFANT Centre), University College Cork, Cork T12 YN60, Ireland

**Author contributions:** Ahearne C aided in the literature review, and contributed to the text and preparation of the manuscript; Boylan G contributed to the manuscript and edited final content; Murray D wrote and edited the manuscript.

**Supported by** The Health Research Board CSA/2012/40.

**Conflict-of-interest** **statement:** There is no conflict of interest associated with either of the authors who contributed to this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Dr. Deirdre Murray,** Department of Paediatrics and Child Health, University College Cork, Western Rd, Cork T12 YN60 Ireland. d.murray@ucc.ie

**Telephone:** +353-21-4205023

**Received:** July 31, 2015

**Peer-review started:** August 3, 2015

**First decision:** October 13, 2015

**Revised:** November 18, 2015

**Accepted:** December 17, 2015

**Article in press:**

**Published online:**

**Abstract**

Interruption of blood flow and gas exchange to the fetus in the perinatal period, known as perinatal asphyxia, can, if significant, trigger a cascade of neuronal injury, leading on to neonatal encephalopathy (NE) and resultant long-term damage. While the majority of infants who are exposed to perinatal hypoxia-ischaemia will recover quickly and go on to have a completely normal survival, a proportion will suffer from an evolving clinical encephalopathy termed hypoxic-ischaemic encephalopathy (HIE) or NE if the diagnosis is unclear. Resultant complications of HIE/NE are wide-ranging and may affect the motor, sensory, cognitive and behavioural outcome of the child. The advent of therapeutic hypothermia as a neuroprotective treatment for those with moderate and severe encephalopathy has improved prognosis. Outcome prediction in these infants has changed, but is more important than ever, as hypothermia is a time sensitive intervention, with a very narrow therapeutic window. To identify those who will benefit from current and emerging neuroprotective therapies we must be able to establish the severity of their injury soon after birth. Currently available indicators such as blood biochemistry, clinical examination and electrophysiology are limited. Emerging biological and physiological markers have the potential to improve our ability to select those infants who will benefit most from intervention. Biomarkers identified from work in proteomics, metabolomics and transcriptomics as well as physiological markers such as heart rate variability, EEG analysis and radiological imaging when combined with neuroprotective measures have the potential to improve outcome in HIE/NE. The aim of this review is to give an overview of the literature in regards to short and long-term outcome following perinatal asphyxia, and to discuss the prediction of this outcome in the early hours after birth when intervention is most crucial; looking at both currently available tools and introducing novel markers.

**Key words:** Perinatal asphyxia; Hypoxic ischaemic encephalopathy; Neurological outcome; Cerebral palsy; Cognitive outcome

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Perinatal asphyxia is a significant cause of acquired brain injury occurring in the neonatal period. A reliable early marker for predicting injury severity and sequelae remains elusive. The advent of therapeutic hypothermia as an effective neuroprotective intervention has changed the prognosis for affected infants. In this review we summarise what is known about the short and long term outcome for infants with perinatal asphyxia in the pre- and post-cooling era. We also describe currently available early indicators of outcome and introduce the exciting field of emerging novel biomarkers, both chemical and physiological.

Ahearne C, Boylan G, Murray D. Short and long term prognosis in perinatal asphyxia: An update. *World J Clin Pediatr* 2015; In press

**Background**

Perinatal asphyxia describes the interruption of blood flow or gas exchange to and from the fetus in the perinatal period[[1](#_ENREF_1)]. This may be prolonged partial asphyxia, sudden sub-total asphyxia due to a sentinel event or a combination of both[[2](#_ENREF_2)]. Hypoxic-ischaemic injury to the brain and vital organs may result if the perinatal asphyxia is of a sufficient degree or prolonged beyond the ability of the fetus to compensate[[3-5](#_ENREF_3)]. Approximately 20 per 1000 deliveries will require significant resuscitation, with biochemical and clinical evidence of perinatal asphyxia[[6](#_ENREF_6)]. Of these only 1.6 per 1000 will go on to develop signs of evolving encephalopathy consistent with hypoxic-ischaemic encephalopathy (HIE)[[7](#_ENREF_7)]. HIE must be differentiated from other causes of neonatal encephalopathy (NE), such as sepsis, meningitis or a metabolic disorder[[1](#_ENREF_1),[8](#_ENREF_8),[9](#_ENREF_9)]. There may be a high suspicion of hypoxic-ischaemic injury following a known perinatal insult such as placental abruption or cord accident or if typical clinical signs, biochemical evidence of metabolic acidosis or depressed Apgar scores are present. However it can be very difficult to make this differentiation quickly after birth[[10](#_ENREF_10)]. Approximately 50%-80% of NE can be attributed to hypoxia-ischaemia and given the potential benefit of early treatment, the need to identify infants with hypoxic-ischaemic induced encephalopathy is becoming increasingly important[[1](#_ENREF_1),[11-13](#_ENREF_11)].

The aim of this review is to provide an overview of the literature on short and long-term outcome following perinatal asphyxia in the pre- and post-cooling era. We also aim to discuss the ability of currently available tools and novel markers to predict outcome in the early hours after birth when intervention is most crucial.

**CURRENT MARKERS FOR PREDICTION OF outcomE**

The advent of therapeutic hypothermia as a neuroprotective treatment for those with moderate and severe encephalopathy has improved prognosis[[14](#_ENREF_14),[15](#_ENREF_15)]. Hypothermia is, however, a time sensitive intervention, with a very narrow therapeutic window and must be instigated within 6 hours or ideally sooner following delivery to be effective[[16](#_ENREF_16)]. So the challenge has become the prompt identification of those infants with signs of perinatal asphyxia who are most at risk of developing moderate or severe HIE. Prompt identification of those who will benefit from current and emerging neuroprotective therapies will help guide appropriate application of resources and permit prognostication. Currently available indicators such as blood biochemistry, clinical examination and electrophysiology all have limitations and their predictive power has been affected by the interceding intervention of therapeutic hypothermia; yet they still remain at the core of our predictive armamentarium in the critical first postnatal hours (Table 1).

***Acid-base balance***

A disturbance in acid-base balance is one of the earliest and most sensitive signs of fetal distress. The degree of acidosis is measured by scalp or cord pH, with acidosis being used to determine the need for intervention. A pH of < 7.00 gives a 50% chance of abnormal outcome, however the positive predictive value for significant encephalopathy is low[[17](#_ENREF_17)]. This prediction might be improved by focusing on metabolic acidosis, and in particular lactate level. However several large trials have shown that lactate monitoring during labour does not improve our ability to detect or prevent adverse labour outcomes compared to pH monitoring alone and may in fact increase rates of instrumental deliveries unnecessarily[[18](#_ENREF_18),[19](#_ENREF_19)].

***Apgar score***

Almost all infants are scored at birth through the eyes of Virginia Apgar, with midwives worldwide using her score for describing the condition of the infant at birth. However, Apgar scores suffer from poor sensitivity and specificity, as 80% of those with an Apgar score of ≤ 7 at 5 min will have a normal outcome[[17](#_ENREF_17)]. Often felt to be useful at extremes, 1 in 5 babies with an Apgar score of 0 at 10 min will survive to school age without moderate or severe disability[[20](#_ENREF_20)]. A further difficulty is the subjective nature of the Apgar score, which leads to high levels of inter-observer variability. Subjective real time clinical scores have been shown to overestimate Apgar scores by a median value of 2.4 compared to later video enhanced estimation[[21](#_ENREF_21)]. Attempts have been made to improve on the conventional Apgar score with Expanded and Combined versions that take aspects of neonatal resuscitation into account[[22](#_ENREF_22),[23](#_ENREF_23)]. In particular, the Combined Apgar score at 5 min after birth has shown some promise in the prediction of perinatal acidosis (sensitivity 97% and specificity 99%) and HIE (*P* = 0.01 if score is < 10), though it cannot distinguish severity of HIE, and long term outcome data is unavailable[[24](#_ENREF_24)].

***Clinical examination***

The neurological examination of a neonate is a clinical skill learnt through experience and exposure. Standardised scores have been developed, and widely used in an attempt to improve interobserver reliability[[25-27](#_ENREF_25)]. However, the examination of a sick neonate is hampered by the need for sedative medications, anti-convulsants and intubation. We have shown that in full term infants, the best prediction of outcome is achieved by the examination at discharge. Examination on the first day after birth, even using a standardised method is not good for the prediction of outcome at two years[[28](#_ENREF_28)]. More recent studies have shown that therapeutic hypothermia reduces our ability to accurately estimate the neurological state of the infant[[29](#_ENREF_29)].

***Electrophysiological monitoring***

Electroencephalography (EEG) and amplitude integrated EEG (aEEG) have both been shown to offer excellent predictive ability as early as 3-6 h following delivery[[30](#_ENREF_30)]. Outcome is strongly linked with the severity of EEG abnormalities seen. EEG and aEEG abnormalities evolve over the first 72 h, and so the timing of the recording is crucial to interpretation[[31](#_ENREF_31)]. Early return of sleep wake cycling and normalization of background EEG abnormalities are good prognostic indicators[[32](#_ENREF_32),[33](#_ENREF_33)]. The link between prognostic ability and timing of this evolution is altered by therapeutic hypothermia, so that delayed recovery may still be associated with a normal outcome[[34](#_ENREF_34)]. A normal EEG recorded soon after birth is highly associated with a normal outcome at 2 years[[35](#_ENREF_35)]. However, an abnormal EEG soon after birth may recover over subsequent days but if it remains abnormal at 48 h a poor prognosis is highly likely[[35](#_ENREF_35)]. The PPV of a severely abnormal aEEG for death or disability at 6 h is 0.63 when assessed by the voltage grading scheme[[34](#_ENREF_34)] and 0.59 when the aEEG is assessed by the pattern grading scheme[[30](#_ENREF_30),[36](#_ENREF_36),[37](#_ENREF_37)]. These values drop slightly but not significantly in cooled infants[[34](#_ENREF_34)]. In experienced hands EEG or aEEG provide an accurate assessment of the grade of encephalopathy and are excellent adjuncts to clinical decision making.

Multichannel EEG monitoring is essential for the detection of neonatal seizures, which occur frequently in infants with moderate and severe HIE. These seizures are difficult to predict or detect clinically and are associated with poor prognosis[[38-41](#_ENREF_38)]. aEEG alone will miss focal or low amplitude seizures and requires expert interpretation[[42](#_ENREF_42),[43](#_ENREF_43)]. We hope that in the future cot-side automated seizure detection tools will be available to improve detection, and thereby the treatment of seizures in HIE[[44](#_ENREF_44)].

**Novel markers for the prediction of outcome**

There is increasing interest in the possibility of developing more accurate, early and reliable markers for predicting long term outcome in HIE. These bio- and physiomarkers may take the form of physiological monitoring (EEG and heart rate variability - HRV), neuroradiological, or biochemical. In fact the ideal marker may be a combination of many of these (Table 1).

Reduced HRV has shown potential for the assessment of HIE severity and the prediction of long term outcomes[[45](#_ENREF_45),[46](#_ENREF_46)].

Radiologically improvements in magnetic resonance imaging has improved our ability to delineate patterns of injury and thereby, aid in prognosis[[47](#_ENREF_47)]. Piglet models of phosphorous-MRS profiles within the first 2 h post-injury can predict the evolution of injury severity[[48](#_ENREF_48)].

Blood biomarkers have also shown promise in predicting injury severity and outcome. Although no definitive blood biomarker has entered into routine clinical use, there are a number which have shown promise based on pilot work in small cohorts. Protein markers, such as UCH-L1, IL-6 and IL-16 and Activin A are altered significantly in cord bloods taken at birth from infants with HIE[[49-51](#_ENREF_49)]. In addition GFAP and S100B have shown elevations slightly later, reaching a peak at 24 h[[49](#_ENREF_49),[52](#_ENREF_52)]. Animal and, more recently, human studies have shown significant alterations in the metabolomic profile of infants with HIE[[53-55](#_ENREF_53)]. Transcriptomics has also shown promise in differentiating infants with perinatal asphyxia and HIE[[56](#_ENREF_56)] Some evidence is also available showing that circulating microRNAs in maternal blood may be useful for the detection of hypoxia in the intrapartum period[[57](#_ENREF_57)]. Other bodily fluids such as urine and CSF have also been the subject of biomarker discovery work[[58](#_ENREF_58)]. A previous meta-analysis by Ramaswamy *et al*[[59](#_ENREF_59)] in this area reported cerebrospinal fluid neuron-specific enolase and IL-1β to be a potential markers of abnormal outcome in survivors.

This list of novel biomarkers is by no means exhaustive but gives an indication of the proactive research ongoing in this rapidly emerging field. In the future one or a combination of these markers may help to offer early, rapid and reliable identification of infants suitable for neuroprotective intervention and may also provide further insight into the complex biochemical responses of the body to hypoxic-ischaemic injury.

**Treatment of HYPOXIC-ICHAEMIC ENCEPHALOPATHY**

Based on substantial evidence from multiple randomized controlled trials, therapeutic hypothermia is now standard of care for infants with moderate and severe HIE in the majority of neonatal units where the necessary resources are available[[14](#_ENREF_14),[15](#_ENREF_15),[60-62](#_ENREF_60)]. Indications for treatment vary somewhat between centres but usually involve some combination of biochemical and clinical evidence of perinatal asphyxia with overt clinical manifestations of encephalopathy often based on the recruitment criteria of the larger trials of therapeutic hypothermia[[60](#_ENREF_60),[61](#_ENREF_61)].

Unfortunately, using these current standard clinical markers, it is estimated that approximately 15%-20% of infants are mis-classified as having either a mild or no encephalopathy and are therefore not offered therapeutic hypothermia, worsening their long term prognosis[[63](#_ENREF_63)].

**Outcome in perinatal asphyxia**

The majority of infants who require significant resuscitation at birth recover quickly and have no signs of encephalopathy. These children, in general have a normal outcome and function in line with their peers academically[[64](#_ENREF_64)]. For this reason, at present, neuroprotective intervention has been reserved for infants with moderate or severe HIE as outlined above. However, several large population based studies now suggest that outcome in children with perinatal asphyxia without clinical encephalopathy is not completely normal. Odd *et al*[[65](#_ENREF_65)] demonstrated an increased risk of low IQ at 8 years in this group compared to a control group. This is concerning due to the potential risk of a huge burden of more subtle disability (Table 2).

**Short term outcome in HIE:**

For those infants who develop HIE, the most commonly used grading system remains the Sarnat score, with infants graded as mild, moderate or severe depending on their clinical signs[[66](#_ENREF_66)]. The approximate breakdown tends to be mild (39%), moderate (39%) and severe (22%)[[7](#_ENREF_7)]. The management and outcome varies significantly with grade of HIE.

Of those with moderate HIE, approximately one third will develop clinical and electrographic seizures in the neonatal period[[39](#_ENREF_39)]. These seizures will usually commence between 18 and 20 h following delivery and will last for minutes to hours[[67](#_ENREF_67)]. Following the cessation of seizures the encephalopathy may gradually improve to the point where oral feeding can recommence and care normalised. Both seizure burden and the time to achieve full oral feeding are useful in predicting the long term outcome of the infant[[39](#_ENREF_39),[41](#_ENREF_41)]. The overall death rate in NE of all grades is 9.9% in developed countries but this rises acutely to 30% among those who qualify for cooling and precipitously to 76.8% when we consider severe encephalopathy alone[[7](#_ENREF_7),[14](#_ENREF_14)].

**Long term outcome in HIE**

Prior to the cooling era approximately 26.4% of infants with NE survived with moderate to severe neurodevelopmental impairment and a further 14% survived with mild impairment. Reported rates of cerebral palsy following NE vary but are generally around 10%-13% among survivors of moderate to severe encephalopathy[[68](#_ENREF_68),[69](#_ENREF_69)]. The risk is increased threefold where there is a history of neonatal seizures[[68](#_ENREF_68)]. Dyskinetic CP and spastic quadriplegia are the most common subtypes with 80% of dyskinetic CP attributable to perinatal hypoxia-ischaemia at term[[69](#_ENREF_69)]. Sensory disruption is also increased following hypoxic-ischaemic injuries. Rates of hearing loss are reported to be as high as 17.1% in those with other persistent neurological deficits[[70](#_ENREF_70)]. Up to 41% of infants with a diagnosis of NE have an abnormality in some element of visual function in the first year of life, and where associated with moderate to severe basal ganglia changes and severe white matter changes on MRI this rises to 100%[[71](#_ENREF_71)].

Therapeutic hypothermia has improved the outlook for infants with moderate to severe HIE, with increased likelihood of survival with normal IQ (RR = 1.31) and improved survival without neurological abnormalities (RR = 1.6) following therapeutic hypothermia at follow-up at 6-7 years of life[[14](#_ENREF_14)].

It is important to note that learning deficits may be present with or without motor or sensory dysfunction. Impairments in episodic memory associated with reduced hippocampal volume has been found in children following perinatal hypoxic-ischaemic injury but without associated neurological deficits[[72](#_ENREF_72)]. Robertson and Finer showed a reduction in school readiness scores as well as attention scores and increases in symptoms of explosiveness and irritability at 5.5 years in survivors of moderate encephalopathy without other disability[[73](#_ENREF_73)]. Marlow *et al*[[74](#_ENREF_74)] also demonstrated memory and attention/executive function impairments in the severe encephalopathy group and increased special educational needs and lower achievement on national curriculum attainment scores in both moderate and severe groups at 7 years[[74](#_ENREF_74)]. Odd *et al*[[64](#_ENREF_64)] have shown that infants with encephalopathy had lower working memory, reading accuracy and comprehension scores and increased requirement for educational support (OR = 6.24) between 8 and 11 years. A Swedish population based study examining the long term outcome following moderate encephalopathy has shown that in late adolescence the rates of disability are even higher, with 30% having CP, and 70% of those without CP having cognitive disability which interfered with their daily life[[75](#_ENREF_75)].

NE has also been associated with increased behavioural difficulties. Those children with a history of moderate and severe encephalopathy have a significant increase in parent and teacher reported hyperactivity[[74](#_ENREF_74)]. There is also a reported increase in autistic spectrum disorders in these children by 5 years (RR = 5.9)[[76](#_ENREF_76)]. Adverse perinatal events are also associated with an increased risk of psychotic symptoms including schizophrenia[[77](#_ENREF_77),[78](#_ENREF_78)].

The longer we follow these children the more evident it becomes that perinatal asphyxia and HIE have significant long term non-motor effects.

**conclusion**

It is important to end with the note that the statistics quoted thus far have predominantly focused on high income countries, where research is most active. However, the greatest burden of disease is in low and middle income countries. Worldwide 10 million infants a year will suffer perinatal respiratory depression, of which 1.15 million will develop clinical encephalopathy. In countries with low neonatal mortality rates (NMR < 5) the incidence of NE is 1.6 per 1000 births rising to 12.1 per 1000 deliveries in countries with high NMR (> 15)[[7](#_ENREF_7)]. It is estimated that 23% of neonatal deaths worldwide can be attributed to asphyxia which equates to nearly 1 million neonatal deaths per year; and in a countries with high neonatal mortality rates the death rate is 8 times that of countries with low NMRs[[79](#_ENREF_79)]. Lack of modern obstetric care, inadequate neonatal resuscitation and lack of therapeutic hypothermia will cause this gap to widen. We need to strive for effective, reliable and inexpensive measures to enable early identification of infants at risk of long term injury, where low cost interventions, such as cooling, are potentially feasible and can produce significant and lifelong improvements on quality of life for these children, their parents and their communities[[80](#_ENREF_80)].

**References**

1 **Volpe JJ**. Neurology of the Newborn. Philadelphia: Saunders, 2001

2 **Fatemi A**, Wilson MA, Johnston MV. Hypoxic-ischemic encephalopathy in the term infant. *Clin Perinatol* 2009; **36**: 835-858, vii [PMID: 19944838 DOI: 10.1016/j.clp.2009.07.011]

3 **Ugwumadu A**. Understanding cardiotocographic patterns associated with intrapartum fetal hypoxia and neurologic injury. *Best Pract Res Clin Obstet Gynaecol* 2013; **27**: 509-536 [PMID: 23702579 DOI: 10.1016/j.bpobgyn.2013.04.002]

4 **Low JA**. Determining the contribution of asphyxia to brain damage in the neonate. *J Obstet Gynaecol Res* 2004; **30**: 276-286 [PMID: 15238103 DOI: 10.1111/j.1447-0756.2004.00194.x]

5 **Parer JT**. Effects of fetal asphyxia on brain cell structure and function: limits of tolerance. *Comp Biochem Physiol A Mol Integr Physiol* 1998; **119**: 711-716 [PMID: 9683410 DOI: 10.1016/S1095-6433(98)01009-5]

6 **Vannucci RC**. Hypoxic-ischemic encephalopathy. *Am J Perinatol* 2000; **17**: 113-120 [PMID: 11012134 DOI: 10.1055/s-2000-9293]

7 **Lee AC**, Kozuki N, Blencowe H, Vos T, Bahalim A, Darmstadt GL, Niermeyer S, Ellis M, Robertson NJ, Cousens S, Lawn JE. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. *Pediatr Res* 2013; **74** Suppl 1: 50-72 [PMID: 24366463 DOI: 10.1038/pr.2013.206]

8 **Edwards AD**, Nelson KB. Neonatal encephalopathies. Time to reconsider the cause of encephalopathies. *BMJ* 1998; **317**: 1537-1538 [PMID: 9836647 DOI: 10.1136/bmj.317.7172.1537]

9 **Nelson KB**, Leviton A. How much of neonatal encephalopathy is due to birth asphyxia? *Am J Dis Child* 1991; **145**: 1325-1331 [PMID: 1835281 DOI: 10.1001/archpedi.1991.02160110117034]

10 **Volpe JJ**. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. *Ann Neurol* 2012; **72**: 156-166 [PMID: 22926849 DOI: 10.1002/ana.23647]

11 **Dammann O**, Ferriero D, Gressens P. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. *Pediatr Res* 2011; **70**: 1-2 [PMID: 21654279 DOI: 10.1203/PDR.0b013e318223f38d]

12 **Cowan F**, Rutherford M, Groenendaal F, Eken P, Mercuri E, Bydder GM, Meiners LC, Dubowitz LM, de Vries LS. Origin and timing of brain lesions in term infants with neonatal encephalopathy. *Lancet* 2003; **361**: 736-742 [PMID: 12620738 DOI: 10.1016/S0140-6736(03)12658-X]

13 **Shah DK**, Lavery S, Doyle LW, Wong C, McDougall P, Inder TE. Use of 2-channel bedside electroencephalogram monitoring in term-born encephalopathic infants related to cerebral injury defined by magnetic resonance imaging. *Pediatrics* 2006; **118**: 47-55 [PMID: 16818548 DOI: 10.1542/peds.2005-1294]

14 **Azzopardi D**, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, Goodwin J, Halliday HL, Juszczak E, Kapellou O, Levene M, Linsell L, Omar O, Thoresen M, Tusor N, Whitelaw A, Edwards AD. Effects of hypothermia for perinatal asphyxia on childhood outcomes. *N Engl J Med* 2014; **371**: 140-149 [PMID: 25006720 DOI: 10.1097/01.ogx.0000458787.40317.4a]

15 **Jacobs SE**, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev* 2013; **1**: CD003311 [PMID: 23440789 DOI: 10.1002/14651858.cd003311.pub3]

16 **Thoresen M**, Tooley J, Liu X, Jary S, Fleming P, Luyt K, Jain A, Cairns P, Harding D, Sabir H. Time is brain: starting therapeutic hypothermia within three hours after birth improves motor outcome in asphyxiated newborns. *Neonatology* 2013; **104**: 228-233 [PMID: 24030160 DOI: 10.1159/000353948]

17 **Ruth VJ**, Raivio KO. Perinatal brain damage: predictive value of metabolic acidosis and the Apgar score. *BMJ* 1988; **297**: 24-27 [PMID: 2457406 DOI: 10.1136/bmj.297.6640.24]

18 **Rorbye C**, Perslev A, Nickelsen C. Lactate versus pH levels in fetal scalp blood during labor - using the Lactate Scout System. *J Matern Fetal Neonatal Med* 2015: 1-5 [PMID: 26004985 DOI: 10.3109/14767058.2015.1045863]

19 **East CE**, Leader LR, Sheehan P, Henshall NE, Colditz PB. Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace. *Cochrane Database Syst Rev* 2010; **5**: CD006174 [PMID: 20238343 DOI: 10.1002/14651858.cd006174.pub2]

20 **Natarajan G**, Shankaran S, Laptook AR, Pappas A, Bann CM, McDonald SA, Das A, Higgins RD, Hintz SR, Vohr BR. Apgar scores at 10 min and outcomes at 6-7 years following hypoxic-ischaemic encephalopathy. *Arch Dis Child Fetal Neonatal Ed* 2013; **98**: F473-F479 [PMID: 23896791 DOI: 10.1136/archdischild-2013-303692]

21 **O'Donnell CP**, Kamlin CO, Davis PG, Carlin JB, Morley CJ. Interobserver variability of the 5-minute Apgar score. *J Pediatr* 2006; **149**: 486-489 [PMID: 17011319 DOI: 10.1016/j.jpeds.2006.05.040]

22 [**Committee on Obstetric Practice, ACOG**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Committee%20on%20Obstetric%20Practice%2C%20ACOG%5BCorporate%20Author%5D); [American Academy of Pediatrics](http://www.ncbi.nlm.nih.gov/pubmed/?term=American%20Academy%20of%20Pediatrics%5BCorporate%20Author%5D); [Committee on Fetus and Newborn, ACOG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Committee%20on%20Fetus%20and%20Newborn%2C%20ACOG%5BCorporate%20Author%5D). ACOG Committee Opinion. Number 333, May 2006 (replaces No. 174, July 1996): The Apgar score. *Obstet Gynecol* 2006; **107**: 1209-1212 [PMID: 16648434]

23 **Rüdiger M**, Braun N, Aranda J, Aguar M, Bergert R, Bystricka A, Dimitriou G, El-Atawi K, Ifflaender S, Jung P, Matasova K, Ojinaga V, Petruskeviciene Z, Roll C, Schwindt J, Simma B, Staal N, Valencia G, Vasconcellos MG, Veinla M, Vento M, Weber B, Wendt A, Yigit S, Zotter H, Küster H. Neonatal assessment in the delivery room--Trial to Evaluate a Specified Type of Apgar (TEST-Apgar). *BMC Pediatr* 2015; **15**: 18 [PMID: 25884954 DOI: 10.1186/s12887-015-0334-7]

24 **Dalili H**, Nili F, Sheikh M, Hardani AK, Shariat M, Nayeri F. Comparison of the four proposed Apgar scoring systems in the assessment of birth asphyxia and adverse early neurologic outcomes. *PLoS One* 2015; **10**: e0122116 [PMID: 25811904 DOI: 10.1371/journal.pone.0122116]

25 **Amiel-Tison C**. A method for neurological evaluation within the first year of life: experience with full-term newborn infants with birth injury. *Ciba Found Symp* 1978; **59**: 107-137 [PMID: 251500 DOI: 10.1002/9780470720417.ch7]

26 **Thompson CM**, Puterman AS, Linley LL, Hann FM, van der Elst CW, Molteno CD, Malan AF. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. *Acta Paediatr* 1997; **86**: 757-761 [PMID: 9240886 DOI: 10.1111/j.1651-2227.1997.tb08581.x]

27 **Dubowitz L**, Ricciw D, Mercuri E. The Dubowitz neurological examination of the full-term newborn. *Ment Retard Dev Disabil Res Rev* 2005; **11**: 52-60 [PMID: 15856443 DOI: 10.1002/mrdd.20048]

28 **Murray DM**, Bala P, O'Connor CM, Ryan CA, Connolly S, Boylan GB. The predictive value of early neurological examination in neonatal hypoxic-ischaemic encephalopathy and neurodevelopmental outcome at 24 months. *Dev Med Child Neurol* 2010; **52**: e55-e59 [PMID: 20041933 DOI: 10.1111/j.1469-8749.2009.03550.x]

29 **Gunn AJ**, Wyatt JS, Whitelaw A, Barks J, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Gluckman PD, Polin RA, Robertson CM, Thoresen M. Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy. *J Pediatr* 2008; **152**: 55-58, 58.e1 [PMID: 18154900]

30 **Toet MC**, Hellström-Westas L, Groenendaal F, Eken P, de Vries LS. Amplitude integrated EEG 3 and 6 hours after birth in full term neonates with hypoxic-ischaemic encephalopathy. *Arch Dis Child Fetal Neonatal Ed* 1999; **81**: F19-F23 [PMID: 10375357 DOI: 10.1136/fn.81.1.F19]

31 **Walsh BH**, Murray DM, Boylan GB. The use of conventional EEG for the assessment of hypoxic ischaemic encephalopathy in the newborn: a review. *Clin Neurophysiol* 2011; **122**: 1284-1294 [PMID: 21550844 DOI: 10.1016/j.clinph.2011.03.032]

32 **de Vries LS**, Hellström-Westas L. Role of cerebral function monitoring in the newborn. *Arch Dis Child Fetal Neonatal Ed* 2005; **90**: F201-F207 [PMID: 15846008 DOI: 10.1136/adc.2004.062745]

33 **Osredkar D**, Toet MC, van Rooij LG, van Huffelen AC, Groenendaal F, de Vries LS. Sleep-wake cycling on amplitude-integrated electroencephalography in term newborns with hypoxic-ischemic encephalopathy. *Pediatrics* 2005; **115**: 327-332 [PMID: 15687440 DOI: 10.1542/peds.2004-0863]

34 **Azzopardi D**. Predictive value of the amplitude integrated EEG in infants with hypoxic ischaemic encephalopathy: data from a randomised trial of therapeutic hypothermia. *Arch Dis Child Fetal Neonatal Ed* 2014; **99**: F80-F82 [PMID: 23800393]

35 **Murray DM**, Boylan GB, Ryan CA, Connolly S. Early EEG findings in hypoxic-ischemic encephalopathy predict outcomes at 2 years. *Pediatrics* 2009; **124**: e459-e467 [PMID: 19706569 DOI: 10.1542/peds.2008-2190]

36 **Hellström-Westas L**. Monitoring brain function with aEEG in term asphyxiated infants before and during cooling. *Acta Paediatr* 2013; **102**: 678-679 [PMID: 23651051 DOI: 10.1111/apa.12287]

37 **Hellström-Westas L**, Rosén I, de Vries LS, Greisen G. Amplitude-integrated EEG Classification and Interpretation in Preterm and Term Infants. *NeoReviews* 2006; **7**: e76-e87 [DOI: 10.1542/neo.7-2-e76]

38 **Murray DM**, Boylan GB, Ali I, Ryan CA, Murphy BP, Connolly S. Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures. *Arch Dis Child Fetal Neonatal Ed* 2008; **93**: F187-F191 [PMID: 17626147 DOI: 10.1136/adc.2005.086314]

39 **Glass HC**, Glidden D, Jeremy RJ, Barkovich AJ, Ferriero DM, Miller SP. Clinical Neonatal Seizures are Independently Associated with Outcome in Infants at Risk for Hypoxic-Ischemic Brain Injury. *J Pediatr* 2009; **155**: 318-323 [PMID: 19540512 DOI: 10.1016/j.jpeds.2009.03.040]

40 **Shah DK**, Wusthoff CJ, Clarke P, Wyatt JS, Ramaiah SM, Dias RJ, Becher JC, Kapellou O, Boardman JP. Electrographic seizures are associated with brain injury in newborns undergoing therapeutic hypothermia. *Arch Dis Child Fetal Neonatal Ed* 2014; **99**: F219-F224 [PMID: 24443407 DOI: 10.1136/archdischild-2013-305206]

41 **Srinivasakumar P**, Zempel J, Trivedi S, Wallendorf M, Rao R, Smith B, Inder T, Mathur AM. Treating EEG Seizures in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial. *Pediatrics* 2015; **136**: e1302-e1309 [PMID: 26482675 DOI: 10.1542/peds.2014-3777]

42 **Shellhaas RA**, Soaita AI, Clancy RR. Sensitivity of amplitude-integrated electroencephalography for neonatal seizure detection. *Pediatrics* 2007; **120**: 770-777 [PMID: 17908764 DOI: 10.1542/peds.2007-0514]

43 **Rennie JM**, Chorley G, Boylan GB, Pressler R, Nguyen Y, Hooper R. Non-expert use of the cerebral function monitor for neonatal seizure detection. *Arch Dis Child Fetal Neonatal Ed* 2004; **89**: F37-F40 [PMID: 14711852 DOI: 10.1136/fn.89.1.F37]

44 [**Mathieson SR**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mathieson%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Stevenson NJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Stevenson%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Low E](http://www.ncbi.nlm.nih.gov/pubmed/?term=Low%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Marnane WP](http://www.ncbi.nlm.nih.gov/pubmed/?term=Marnane%20WP%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Rennie JM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rennie%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Temko A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Temko%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Lightbody G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lightbody%20G%5BAuthor%5D&cauthor=true&cauthor_uid=26055336), [Boylan GB](http://www.ncbi.nlm.nih.gov/pubmed/?term=Boylan%20GB%5BAuthor%5D&cauthor=true&cauthor_uid=26055336). Validation of an automated seizure detection algorithm for term neonates. *Clin Neurophysiol* 2015: Epub ahead of print [PMID: 26055336 DOI: 10.1016/j.clinph.2015.04.075]

45 **Vergales BD**, Zanelli SA, Matsumoto JA, Goodkin HP, Lake DE, Moorman JR, Fairchild KD. Depressed heart rate variability is associated with abnormal EEG, MRI, and death in neonates with hypoxic ischemic encephalopathy. *Am J Perinatol* 2014; **31**: 855-862 [PMID: 24347263 DOI: 10.1055/s-0033-1361937]

46 **Goulding RM**, Stevenson NJ, Murray DM, Livingstone V, Filan PM, Boylan GB. Heart rate variability in hypoxic ischemic encephalopathy: correlation with EEG grade and 2-y neurodevelopmental outcome. *Pediatr Res* 2015; **77**: 681-687 [PMID: 25665054]

47 **de Vries LS**, Groenendaal F. Patterns of neonatal hypoxic-ischaemic brain injury. *Neuroradiology* 2010; **52**: 555-566 [PMID: 20390260 DOI: 10.1007/s00234-010-0674-9]

48 **Cady EB**, Iwata O, Bainbridge A, Wyatt JS, Robertson NJ. Phosphorus magnetic resonance spectroscopy 2 h after perinatal cerebral hypoxia-ischemia prognosticates outcome in the newborn piglet. *J Neurochem* 2008; **107**: 1027-1035 [PMID: 18786177 DOI: 10.1111/j.1471-4159.2008.05662.x]

49 **Chalak LF**, Sánchez PJ, Adams-Huet B, Laptook AR, Heyne RJ, Rosenfeld CR. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. *J Pediatr* 2014; **164**: 468-74.e1 [PMID: 24332821]

50 **Walsh BH**, Boylan GB, Livingstone V, Kenny LC, Dempsey EM, Murray DM. Cord blood proteins and multichannel-electroencephalography in hypoxic-ischemic encephalopathy. *Pediatr Crit Care Med* 2013; **14**: 621-630 [PMID: 23823198 DOI: 10.1097/PCC.0b013e318291793f]

51 **Florio P**, Frigiola A, Battista R, Abdalla Ael H, Gazzolo D, Galleri L, Pinzauti S, Abella R, Li Volti G, Strambi M. Activin A in asphyxiated full-term newborns with hypoxic ischemic encephalopathy. *Front Biosci* (Elite Ed) 2010; **2**: 36-42 [PMID: 20036850 DOI: 10.2741/e62]

52 **Gazzolo D**, Abella R, Marinoni E, di Iorio R, Li Volti G, Galvano F, Frigiola A, Temporini F, Moresco L, Colivicchi M, Sabatini M, Ricotti A, Strozzi MC, Crivelli S, Risso FM, Sannia A, Florio P. New markers of neonatal neurology. *J Matern Fetal Neonatal Med* 2009; **22** Suppl 3: 57-61 [PMID: 19718579 DOI: 10.1080/14767050903181468]

53 **Solberg R**, Enot D, Deigner HP, Koal T, Scholl-Bürgi S, Saugstad OD, Keller M. Metabolomic analyses of plasma reveals new insights into asphyxia and resuscitation in pigs. *PLoS One* 2010; **5**: e9606 [PMID: 20231903 DOI: 10.1371/journal.pone.0009606]

54 **Walsh BH**, Broadhurst DI, Mandal R, Wishart DS, Boylan GB, Kenny LC, Murray DM. The metabolomic profile of umbilical cord blood in neonatal hypoxic ischaemic encephalopathy. *PLoS One* 2012; **7**: e50520 [PMID: 23227182 DOI: 10.1371/journal.pone.0050520]

55 **Denihan NM**, Boylan GB, Murray DM. Metabolomic profiling in perinatal asphyxia: a promising new field. *Biomed Res Int* 2015; **2015**: 254076 [PMID: 25802843 DOI: 10.1155/2015/254076]

56 **Looney AM**, Walsh BH, Moloney G, Grenham S, Fagan A, O'Keeffe GW, Clarke G, Cryan JF, Dinan TG, Boylan GB, Murray DM. Downregulation of Umbilical Cord Blood Levels of miR-374a in Neonatal Hypoxic Ischemic Encephalopathy. *J Pediatr* 2015; **167**: 269-73.e2 [PMID: 26001314 DOI: 10.1016/j.jpeds.2015.04.060]

57 **Whitehead CL**, Teh WT, Walker SP, Leung C, Larmour L, Tong S. Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. *PLoS One* 2013; **8**: e78487 [PMID: 24282500 DOI: 10.1371/journal.pone.0078487]

58 **Lv H**, Wang Q, Wu S, Yang L, Ren P, Yang Y, Gao J, Li L. Neonatal hypoxic ischemic encephalopathy-related biomarkers in serum and cerebrospinal fluid. *Clin Chim Acta* 2015; **450**: 282-297 [PMID: 26320853 DOI: 10.1016/j.cca.2015.08.021]

59 **Ramaswamy V**, Horton J, Vandermeer B, Buscemi N, Miller S, Yager J. Systematic review of biomarkers of brain injury in term neonatal encephalopathy. *Pediatr Neurol* 2009; **40**: 215-226 [PMID: 19218035 DOI: 10.1016/j.pediatrneurol.2008.09.026]

60 **Azzopardi DV**, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P. Moderate hypothermia to treat perinatal asphyxial encephalopathy. *N Engl J Med* 2009; **361**: 1349-1358 [PMID: 19797281 DOI: 10.1056/NEJMoa0900854]

61 **Gluckman PD**, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet* 2005; **365**: 663-670 [PMID: 15721471 DOI: 10.1016/S0140-6736(05)70932-6]

62 **Guillet R**, Edwards AD, Thoresen M, Ferriero DM, Gluckman PD, Whitelaw A, Gunn AJ. Seven- to eight-year follow-up of the CoolCap trial of head cooling for neonatal encephalopathy. *Pediatr Res* 2012; **71**: 205-209 [PMID: 22258133 DOI: 10.1038/pr.2011.30]

63 **DuPont TL**, Chalak LF, Morriss MC, Burchfield PJ, Christie L, Sánchez PJ. Short-term outcomes of newborns with perinatal acidemia who are not eligible for systemic hypothermia therapy. *J Pediatr* 2013; **162**: 35-41 [PMID: 22871488 DOI: 10.1016/j.jpeds.2012.06.042]

64 **Odd DE**, Whitelaw A, Gunnell D, Lewis G. The association between birth condition and neuropsychological functioning and educational attainment at school age: a cohort study. *Arch Dis Child* 2011; **96**: 30-37 [PMID: 20705720 DOI: 10.1136/adc.2009.176065]

65 **Odd DE**, Lewis G, Whitelaw A, Gunnell D. Resuscitation at birth and cognition at 8 years of age: a cohort study. *Lancet* 2009; **373**: 1615-1622 [PMID: 19386357 DOI: 10.1016/S0140-6736(09)60244-0]

66 **Sarnat HB**, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. *Arch Neurol* 1976; **33**: 696-705 [PMID: 987769 DOI: 10.1001/archneur.1976.00500100030012]

67 **Filan P**, Boylan GB, Chorley G, Davies A, Fox GF, Pressler R, Rennie JM. The relationship between the onset of electrographic seizure activity after birth and the time of cerebral injury in utero. *BJOG* 2005; **112**: 504-507 [PMID: 15777453 DOI: 10.1111/j.1471-0528.2004.00476.x]

68 **Dixon G**, Badawi N, Kurinczuk JJ, Keogh JM, Silburn SR, Zubrick SR, Stanley FJ. Early developmental outcomes after newborn encephalopathy. *Pediatrics* 2002; **109**: 26-33 [PMID: 11773538 DOI: 10.1542/peds.109.1.26]

69 **Rennie JM**, Hagmann CF, Robertson NJ. Outcome after intrapartum hypoxic ischaemia at term. *Semin Fetal Neonatal Med* 2007; **12**: 398-407 [PMID: 17825633 DOI: 10.1016/j.siny.2007.07.006]

70 **Jiang ZD**. Long-term effect of perinatal and postnatal asphyxia on developing human auditory brainstem responses: peripheral hearing loss. *Int J Pediatr Otorhinolaryngol* 1995; **33**: 225-238 [PMID: 8557479 DOI: 10.1016/0165-5876(95)01213-3]

71 **Mercuri E**, Anker S, Guzzetta A, Barnett AL, Haataja L, Rutherford M, Cowan F, Dubowitz L, Braddick O, Atkinson J. Visual function at school age in children with neonatal encephalopathy and low Apgar scores. *Arch Dis Child Fetal Neonatal Ed* 2004; **89**: F258-F262 [PMID: 15102732 DOI: 10.1136/adc.2002.025387]

72 **Gadian DG**, Aicardi J, Watkins KE, Porter DA, Mishkin M, Vargha-Khadem F. Developmental amnesia associated with early hypoxic-ischaemic injury. *Brain* 2000; **123** Pt 3: 499-507 [PMID: 10686173 DOI: 10.1093/brain/123.3.499]

73 **Robertson CM**, Finer NN. Educational readiness of survivors of neonatal encephalopathy associated with birth asphyxia at term. *J Dev Behav Pediatr* 1988; **9**: 298-306 [PMID: 2976068]

74 **Marlow N**, Rose AS, Rands CE, Draper ES. Neuropsychological and educational problems at school age associated with neonatal encephalopathy. *Arch Dis Child Fetal Neonatal Ed* 2005; **90**: F380-F387 [PMID: 16113154 DOI: 10.1136/adc.2004.067520]

75 **Lindström K**, Hallberg B, Blennow M, Wolff K, Fernell E, Westgren M. Moderate neonatal encephalopathy: pre- and perinatal risk factors and long-term outcome. *Acta Obstet Gynecol Scand* 2008; **87**: 503-509 [PMID: 18446532 DOI: 10.1080/00016340801996622]

76 **Badawi N**, Dixon G, Felix JF, Keogh JM, Petterson B, Stanley FJ, Kurinczuk JJ. Autism following a history of newborn encephalopathy: more than a coincidence? *Dev Med Child Neurol* 2006; **48**: 85-89 [PMID: 16417661 DOI: 10.1017/S001216220600020X]

77 **Zammit S**, Odd D, Horwood J, Thompson A, Thomas K, Menezes P, Gunnell D, Hollis C, Wolke D, Lewis G, Harrison G. Investigating whether adverse prenatal and perinatal events are associated with non-clinical psychotic symptoms at age 12 years in the ALSPAC birth cohort. *Psychol Med* 2009; **39**: 1457-1467 [PMID: 19215630 DOI: 10.1017/S0033291708005126]

78 **de Haan M**, Wyatt JS, Roth S, Vargha-Khadem F, Gadian D, Mishkin M. Brain and cognitive-behavioural development after asphyxia at term birth. *Dev Sci* 2006; **9**: 350-358 [PMID: 16764608 DOI: 10.1111/j.1467-7687.2006.00499.x]

79 **Lawn JE**, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? *Lancet* 2005; **365**: 891-900 [PMID: 15752534 DOI: 10.1016/S0140-6736(05)71048-5]

80 **Kali GT**, Martinez-Biarge M, Van Zyl J, Smith J, Rutherford M. Management of therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy in a tertiary centre in South Africa. *Arch Dis Child Fetal Neonatal Ed* 2015; **100**: F519-F523 [PMID: 26126846 DOI: 10.1136/archdischild-2015-308398]

**P-Reviewer:** Al-Biltagi M, Sangkhathat S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Predictors of outcome**

|  |  |  |
| --- | --- | --- |
| Predictors of outcome | Pros  | Cons |
| Standard |  |  |
| Acid-base balance | Widely available test, can be measured early by scalp and cord sampling | Cannot differentiate degree of severity of injury, invasive testing |
| pH | Responds early to HI  | Low PPV for abnormal outcome |
| Lactate | Better reflects metabolic mechanism | No advantage over pH  |
| Apgar score | Quick assessment of neonatal condition at birth, non-invasive | High inter-observer variablility, poor predictor of long-term outcome |
| Clinical examination | Non-invasive, good to track changes in clinical state as injury evolves, predictive at discharge | Requires clinical experience, affected by intubation and medications and hypothermia, poor predictor of long-term outcome |
| EEG/aEEG | “Gold standard”, early predictive value if normal, value of subclinical seizure detection, non-invasive | Requires resources, equipment to apply, clinical expertise to interpret |
| Novel |  |  |
| HRV | Differentiates severity of HIE, non-invasive | Requires specialist equipment |
| MRI/MRS | Specific patterns of injury aid prognosis, early changes apparent | Requires specialist equipment, requires transfer of sick infant to MRI machine/department, requires infant to remain still for prolonged periods |
| Biomarkers | Very promising in pilot studies | None validated for clinical use |
| Serum | Reflects systemic biochemical state | Mixed markers from cerebral and other organ dysfunction, only small volumes available, invasive testing |
| Cord blood | Large volumes possible, available early | Mixture of fetal and placental blood  |
| CSF  | Reflects cerebral markers | Very difficult to sample |
| Urine | Relatively easy to sample | Affected if significant renal disease |
|  |  |  |
| Proteomics | Relatively stable and easy to test | Requires specialist equipment, response to injury may be delayed |
| Metabolomics | Rapidly responsive to changes in biochemical state  | Requires specialist equipment, highly sensitive to environmental factors |
| Transcriptomics | Involved in critical processes of cell cycle and cell death, very stable | Requires specialist equipment, most markers are completely novel and difficult to identify, they may also regulate multiple pathways |

The current standard tools and the novel emerging techniques to predict outcome in perinatal asphyxia are outlined with their respective advantages and disadvantages. HI: Hypoxia-ischaemia; EEG: Electroencephalograph; aEEG: Amplitude-integrated electroencephalograph; HRV: Heart rate variability; MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; HIE: Hypoxic-ischaemic encephalopathy; CSF: Cerebrospinal fluid.

**Table 2 Outcomes in perinatal asphyxia**

|  |  |  |
| --- | --- | --- |
| Short-term |  |  |
|  | Death |  |
|  | HIE  |  |
|  | Seizures |  |
| Long-term  |  |  |
|  | Motor  | Cerebral palsy |
|  | Sensory | Hearing loss |
|  |  | Visual impairment |
|  | Cognitive  | Episodic and working memory |
|  |  | Attention |
|  | Educational | Increased support requirements |
|  |  | Lower test scores |
|  | Behavioural | Attention |
|  |  | Explosiveness |
|  |  | Irritability |
|  | Neuropsychiatric | Psychotic symptoms |
|  | Neurodevelopmental | Autistic Spectrum  |

A summary table of reported outcomes in perinatal asphyxia and hypoxic-ischaemic encephalopathy.